Omeros Corporation (NASDAQ:OMER) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Omeros Corporation (NASDAQ:OMER) have been assigned an average rating of “Moderate Buy” from the five brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $40.3333.

A number of research analysts have recently weighed in on OMER shares. D. Boral Capital reaffirmed a “buy” rating and set a $36.00 price objective on shares of Omeros in a research report on Tuesday, January 27th. Wall Street Zen cut shares of Omeros from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Omeros in a report on Thursday, January 22nd. Finally, HC Wainwright increased their price objective on shares of Omeros from $20.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th.

Omeros Stock Up 0.2%

Shares of NASDAQ OMER opened at $12.04 on Friday. The firm’s 50-day moving average price is $12.38 and its 200-day moving average price is $8.38. Omeros has a 52-week low of $2.95 and a 52-week high of $17.65. The company has a market cap of $853.64 million, a PE ratio of -5.96 and a beta of 2.44.

Insiders Place Their Bets

In related news, CAO David J. Borges sold 30,000 shares of the company’s stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $12.31, for a total transaction of $369,300.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 12.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Omeros

Large investors have recently added to or reduced their stakes in the stock. State of Wyoming bought a new position in Omeros during the 4th quarter worth about $25,000. B. Riley Wealth Advisors Inc. bought a new stake in shares of Omeros in the 2nd quarter valued at about $32,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Omeros in the 4th quarter worth approximately $33,000. Harbour Investments Inc. boosted its stake in shares of Omeros by 46.1% during the second quarter. Harbour Investments Inc. now owns 13,469 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 4,251 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Omeros by 829.6% during the second quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 11,971 shares in the last quarter. 48.79% of the stock is owned by hedge funds and other institutional investors.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.